Literature DB >> 10603400

Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.

H W Murray1, S Delph-Etienne.   

Abstract

In experimental visceral leishmaniasis, in which the tissue macrophage is the target, in vivo responsiveness to conventional chemotherapy (pentavalent antimony [Sb]) requires a T-cell-dependent mechanism. To determine if this mechanism involves gamma interferon (IFN-gamma)-induced activation and/or specific IFN-gamma-regulated macrophage leishmanicidal mechanisms (generation of reactive nitrogen or oxygen intermediates, we treated gene-deficient mice infected with Leishmania donovani. In IFN-gamma gene knockout (GKO) mice, Sb inhibited but did not kill intracellular L. donovani (2% killing versus 76% in controls). Sb was active (>94% killing), however, in both inducible nitric oxide synthase (iNOS) knockout (KO) and respiratory burst (phagocyte oxidase)-deficient chronic granulomatous disease (X-CGD) mice. Sb's efficacy was also maintained in doubly deficient animals (X-CGD mice treated with an iNOS inhibitor). In contrast to Sb, amphotericin B (AmB) induced high-level killing in GKO mice; AmB was also fully active in iNOS KO and X-CGD animals. Although resolution of L. donovani infection requires iNOS, residual visceral infection remained largely suppressed in iNOS KO mice treated with Sb or AmB. These results indicate that endogenous IFN-gamma regulates the leishmanicidal response to Sb and achieves this effect via a pathway unrelated to the macrophage's primary microbicidal mechanisms. The role of IFN-gamma is selective, since it is not a cofactor in the response to AmB. Treatment with either Sb or AmB permits an iNOS-independent mechanism to emerge and control residual intracellular L. donovani infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603400      PMCID: PMC97133          DOI: 10.1128/IAI.68.1.288-293.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

Review 1.  Kala-azar as an AIDS-related opportunistic infection.

Authors:  H W Murray
Journal:  AIDS Patient Care STDS       Date:  1999-08       Impact factor: 5.078

2.  Amphotericin B induces tumor necrosis factor production by murine macrophages.

Authors:  J K Chia; M Pollack
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

3.  Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells.

Authors:  J R Perfect; D L Granger; D T Durack
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

4.  Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes.

Authors:  H W Murray
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

Review 5.  Antifungal agents useful in therapy of systemic fungal infections.

Authors:  G Medoff; J Brajtburg; G S Kobayashi; J Bolard
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

6.  Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model.

Authors:  A Vecchiarelli; G Verducci; S Perito; P Puccetti; P Marconi; F Bistoni
Journal:  J Antibiot (Tokyo)       Date:  1986-06       Impact factor: 2.649

7.  Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.

Authors:  J J Stern; M J Oca; B Y Rubin; S L Anderson; H W Murray
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

8.  Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1).

Authors:  L E Adinolfi; P F Bonventre
Journal:  Am J Trop Med Hyg       Date:  1985-03       Impact factor: 2.345

9.  Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.

Authors:  H W Murray; J D Berman; S D Wright
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

10.  Amphotericin B activation of human genes encoding for cytokines.

Authors:  P D Rogers; J K Jenkins; S W Chapman; K Ndebele; B A Chapman; J D Cleary
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  48 in total

1.  Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

Authors:  H W Murray
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.

Authors:  M Soto; C Alonso; J M Requena
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

4.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

7.  Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.

Authors:  Karina Corware; Debra Harris; Ian Teo; Matthew Rogers; Kikkeri Naresh; Ingrid Müller; Sunil Shaunak
Journal:  Biomaterials       Date:  2011-07-31       Impact factor: 12.479

8.  Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Authors:  Vasundhra Bhandari; Shyam Sundar; Jean Claude Dujardin; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Authors:  Henry W Murray; Yunhua Zhang; Yan Zhang; Vanitha S Raman; Steven G Reed; Xiaojing Ma
Journal:  Infect Immun       Date:  2013-04-15       Impact factor: 3.441

10.  A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Gaurav Gupta; Kevin J Peine; Dalia Abdelhamid; Heidi Snider; Andrew B Shelton; Latha Rao; Sainath R Kotha; Andrew C Huntsman; Sanjay Varikuti; Steve Oghumu; C Benjamin Naman; Li Pan; Narasimham L Parinandi; Tracy L Papenfuss; A Douglas Kinghorn; Eric M Bachelder; Kristy M Ainslie; James R Fuchs; Abhay R Satoskar
Journal:  ACS Infect Dis       Date:  2015-09-21       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.